Edgewise Therapeutics, Inc.   Report issue

For profit Phase 1
Founded: Boulder CO United States (2017)

Organization Overview

First Clinical Trial
2020
NCT04585464
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Edgewise Therapeutics, Inc.